Publication | Closed Access

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation

InflammationBreast OncologyMedicineImmunologyInflammatory MarkerBreast CancerPharmacotherapySystemic InflammationCancer TreatmentOncologyRadiation OncologyC-reactive Protein